Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol
1998

Impact of Age on Survival in Multiple Myeloma Patients

Sample size: 341 publication Evidence: high

Author Information

Author(s): A Riccardi, O Mora, S Brugnatelli, C Tinelli, R Spanedda, A De Paoli, L Barbarano, M Di Stasi, C Bergonzi, M Giordano, C Delfini, G Nicoletti, E Rinaldi, L Piccininil, D Valentini, E Ascari

Primary Institution: Universita e Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, Pavia, Italy

Hypothesis

Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy.

Conclusion

Younger patients with multiple myeloma treated with chemotherapy tend to survive longer than older patients.

Supporting Evidence

  • 271 out of 341 patients had died by May 1996.
  • Median survival for patients aged > 66 years was 31 months, while for those < 66 years it was 44 months.
  • Among patients < 55 years, median survival was 57 months.
  • 32% of patients < 66 years survived over 72 months compared to 17% of patients > 66 years.

Takeaway

If you're younger when you get treated for multiple myeloma, you might live longer than if you're older.

Methodology

Patients were treated with chemotherapy in a prospective, multicentre, randomized protocol and survival was evaluated based on age groups.

Limitations

The study may not account for all variables affecting survival, such as the type of chemotherapy received.

Participant Demographics

Patients were previously untreated with multiple myeloma, with a median age of 66 years.

Statistical Information

P-Value

0.00095

Statistical Significance

p<0.00095

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication